

VPRIV® (velaglucerase alfa) (Intravenous)

Document Number: MH-0141

Last Review Date: 09/01/2021

Date of Origin: 01/01/2012

Dates Reviewed: 12/2011, 02/2013, 02/2014, 09/2014, 07/2015, 07/2016, 08/2017, 07/2018, 07/2019, 07/2020, 09/2021

I. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Vpriv 400 unit powder for injection: 18 vials per 14 days

B. Max Units (per dose and over time) [HCPC Unit]:

- 72 billable units every 14 days

III. Initial Approval Criteria ^{1,9-12}

Patient is required to meet Site of Service specialty infusion program requirements (refer to the [Medica Site of Service Policy](#)).

Coverage is provided in the following conditions:

- Patient is at least 4 years of age; **AND**

Universal Criteria

- Must be used as a single agent; **AND**

Type 1 Gaucher's Disease † Φ

- Patient has a documented diagnosis of Type 1 Gaucher Disease as confirmed by beta-glucosidase leukocyte (BGL) test with significantly reduced or absent glucocerebrosidase enzyme activity; **AND**
- Adults only (i.e., patients at least 18 years or older): Patient's disease results in one or more of the following:

- Anemia [*i.e.*, hemoglobin less than or equal to 11 g/dL (women) or 12 g/dL (men)] not attributed to iron, folic acid, or vitamin B12 deficiency; **OR**
- Moderate to severe hepatomegaly (liver size 1.25 or more times normal) OR splenomegaly (spleen size 5 or more times normal); **OR**
- Skeletal disease (e.g., lesions, remodeling defects and/or deformity of long bones, osteopenia/osteoporosis, etc.); **OR**
- Symptomatic disease (e.g., bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.); **OR**
- Thrombocytopenia (platelet count less than or equal to 120,000/mm³)

† FDA Approved Indication(s), **Φ** Orphan Drug

IV. Renewal Criteria ^{1,9-12}

Coverage can be renewed based on the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by one or more of the following (compared to pre-treatment baseline):
 - Improvement in symptoms (e.g., bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.)
 - Reduction in size of liver or spleen
 - Improvement in hemoglobin/anemia
 - Improvement in skeletal disease (e.g., increase in lumbar spine and/or femoral neck BMD, no bone crises or bone fractures, etc.)
 - Improvement in platelet counts; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, etc.

V. Dosage/Administration¹

| Indication | Dose |
|------------------------|--|
| Type 1 Gaucher Disease | Administer up to 60 units/kg every other week as an intravenous infusion |

VI. Billing Code/Availability Information

HCPCS code:

- J3385 – Injection, velaglucerase alfa, 100 units: 1 billable unit = 100 units

NDC:

- Vpriv 400 unit powder for injection: 54092-0701-xx

VII. References

1. VPRIV [package insert]. Cambridge, MA; Shire Human Genetic Therapies; December 2020. Accessed August 2021.
2. Anderson HC, et al. Consensus Statement by the International Collaborative Gaucher Group (ICGG) U.S. Coordinators on Individualization of ERT for Type-1 Gaucher Disease. September, 2000.
3. Charrow, et al. Gaucher Disease: Recommendations on Diagnosis, Evaluation and Monitoring (Special Article). Archives of Internal Medicine 1998; 158:1754-1760.
4. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.
5. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.
6. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835.
7. Martins AM, Valadares ER, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009 Oct;155(4 Suppl):S10-8.
8. Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease Type 1 in the United States. Mol Genet Metab. 2016 Feb; 117(2):95-103. Doi: `0.1016/j.ymgme.2015.09.002. Epub 2015 Sep 7.
9. Gonzalez DE, Turkia HB, Lukina EA, et al. Enzyme Replacement Therapy With Velaglucerase Alfa in Gaucher Disease: Results From a Randomized, Double-Blind, Multinational, Phase 3 Study. Am J Hematol 2013 Mar;88(3):166-71. doi:10.1002/ajh.23381. Epub 2013 Feb 6.
10. Zimran A, Pastores G, Szymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. Author manuscript; available in PMC 2014 Mar 1. Published in final edited form as: Am J Hematol. 2013 Mar; 88(3): 172–178. Published online 2013 Jan 22. doi: 10.1002/ajh.23383.
11. Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells, Molecules and Diseases 68 (2018) 203-208.
12. DuaPuri R, Kapoor S, Kishnani PS, et al. Diagnosis and Management of Gaucher Disease in India – Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatrics. 5;2018: 143-153.

Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description |
|--------|--------------------|
| E75.22 | Gaucher disease |

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) Local Coverage Determinations (LCDs), and Local Coverage Articles may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions | | |
|---|---|---|
| Jurisdiction | Applicable State/US Territory | Contractor |
| E (1) | CA, HI, NV, AS, GU, CNMI | Noridian Healthcare Solutions, LLC |
| F (2 & 3) | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ | Noridian Healthcare Solutions, LLC |
| 5 | KS, NE, IA, MO | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6 | MN, WI, IL | National Government Services, Inc. (NGS) |
| H (4 & 7) | LA, AR, MS, TX, OK, CO, NM | Novitas Solutions, Inc. |
| 8 | MI, IN | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9) | FL, PR, VI | First Coast Service Options, Inc. |
| J (10) | TN, GA, AL | Palmetto GBA, LLC |
| M (11) | NC, SC, WV, VA (excluding below) | Palmetto GBA, LLC |
| L (12) | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc. |
| K (13 & 14) | NY, CT, MA, RI, VT, ME, NH | National Government Services, Inc. (NGS) |
| 15 | KY, OH | CGS Administrators, LLC |